FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Megna Michael R				2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [ KNSA ]								(Ch	eck all appli Directo Y Officer	r 10% Owner (give title Other (specif			ner	
(Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET				3. Date of Earliest Transaction (Month/Day/Year) 09/02/2021									Chief Accounting Officer					
(Street) HAMILT		-	HM11 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(0)				Doriva	tivo 9	Soc	uritio	<u> </u>	auired D	iene	nead o	of or Ro	neficial	ly Owner				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transar Date (Month/Date)			ction 2A. Deemed Execution Date,			3. Transaction Dis		4. Securi Disposed	curities Acquired (A) or osed Of (D) (Instr. 3, 4 a		5. Amou Securitie Benefici	nt of es ally Following	6. Ownershi Form: Direc (D) or Indire (I) (Instr. 4)	t o	7. Nature of Indirect Beneficial Ownership			
								Code	, ,	Amount	(A) o (D)	r Price	Transaci (Instr. 3	tion(s)		"	(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	ransaction of I ode (Instr. Derivative (		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	(D) rect	Beneficial Ownership (Instr. 4)			
				Co	ode V	,	(A)	(D)	Date Exercisable	Exp	oiration e	Title	Amount or Number of Shares					
Share Option	\$12.97	09/02/2021			A		6,195		(1)	09/0	01/2031	Class A Common Shares	6,195	\$0	6,195	Г		
Restricted Share Units	(2)	09/02/2021			A		3,098		(3)		(3)	Class A Common Shares	3,098	\$0	3,098	Г		

## Explanation of Responses:

- 1. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
- 2. Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.
- 3. The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

/s/ Madelyn Zeylikman,

Attorney-in-Fact for Michael 09/07/2021

R. Megna

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.